
Novartis exploring almost $14-billion stake sale in Roche – reports
pharmafile | April 26, 2016 | News story | Manufacturing and Production, Sales and Marketing |Â Â Financial, Merger & Acquisition, Novartis, Roche, Stake saleÂ
Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: ROG) worth nearly $14 billion, according to reports.
Novartis bought and subsequently raised its stake to about 6% in Roche between 2001 and 2003 in what was an unsuccessful bid for a merger.
Novartis may sell the stake via an order book process involving certain investors partly to earn a premium on the current trading price, according to reports.
Last week, Novartis posted a 13% drop in net income for the first quarter on the back of falling sales for its bestselling cancer drug Gleevec as generic version of the therapy hit the markets.
The company reported net income of $2.01 billion. Sales were down 3% year-on-year to $11.6 billion impacted by currency movements, cost of new drug launches and restructuring costs.
Anjali Shukla
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






